Byetta provided greater glycemic durability and overall glycemic control than amaryl in patients with type 2 diabetes Full Text
Amylin Pharmaceuticals, 06/12/2012
Amylin Pharmaceuticals, Inc. announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA (exenatide) injection resulted in greater glycemic durability and overall glycemic control than Amaryl (glimepiride) in patients with type 2 diabetes uncontrolled on metformin alone. These clinical study findings are being presented at the 2012 ADA/The Lancet Symposium today at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia and will be published in the diabetes–themed issue of The Lancet.



